Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice

被引：29

作者：

Pirker, Robert ^{[1
]}

Filipits, Martin ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria

来源：

CANCER AND METASTASIS REVIEWS | 2016年 / 35卷 / 01期

关键词：

ALK; Biomarker; Cetuximab; EGFR mutations; Liquid biopsy; Necitumumab; CHEMOTHERAPY PLUS CETUXIMAB; PHASE-III TRIAL; 1ST-LINE THERAPY; OPEN-LABEL; EGFR MUTATIONS; DNA-REPAIR; RESISTANCE; CISPLATIN; GEMCITABINE; CRIZOTINIB;

D O I：

10.1007/s10555-016-9612-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Personalized treatment of patients with advanced non-small-cell lung cancer based on clinical and molecular tumor features has entered clinical routine practice. The 2015 pathological classification of lung cancer mandates immunohistochemical and molecular analysis. Therapeutic strategies focused on inhibition of angiogenesis and growth factor receptor signaling. Inhibitors of angiogenesis and monoclonal antibodies directed against the epidermal growth factor receptor have shown efficacy in combination with chemotherapy. Mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase have become clinically relevant therapeutic targets. Immune checkpoint inhibitors are also entering routine clinical practice. Identification of predictive biomarkers is essential and faces several challenges including tumor heterogeneity and dynamic changes of tumor features over time. Liquid biopsies may overcome some of these challenges in the future.

引用

页码：141 / 150

页数：10

共 65 条

[1] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[2]

[Anonymous], 16 WORLD C LUNG CANC

[3]

[Anonymous], LUNG CANC

[4]

[Anonymous], 16 WORLD C LUNG CANC

[5]

[Anonymous], CLIN CANC RES

[6] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].

Azzoli, Christopher G. ;

Baker, Sherman, Jr. ;

Temin, Sarah ;

Pao, William ;

Aliff, Timothy ;

Brahmer, Julie ;

Johnson, David H. ;

Laskin, Janessa L. ;

Masters, Gregory ;

Milton, Daniel ;

Nordquist, Luke ;

Pfister, David G. ;

Piantadosi, Steven ;

Schiller, Joan H. ;

Smith, Reily ;

Smith, Thomas J. ;

Strawn, John R. ;

Trent, David ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Acquired resistance to TKIs in solid tumours: learning from lung cancer [J].

Camidge, D. Ross ;

Pao, William ;

Sequist, Lecia V. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (08) :473-481

[9]

Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]

[10] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer [J].

Cross, Darren A. E. ;

Ashton, Susan E. ;

Ghiorghiu, Serban ;

Eberlein, Cath ;

Nebhan, Caroline A. ;

Spitzler, Paula J. ;

Orme, Jonathon P. ;

Finlay, M. Raymond V. ;

Ward, Richard A. ;

Mellor, Martine J. ;

Hughes, Gareth ;

Rahi, Amar ;

Jacobs, Vivien N. ;

Brewer, Monica Red ;

Ichihara, Eiki ;

Sun, Jing ;

Jin, Hailing ;

Ballard, Peter ;

Al-Kadhimi, Katherine ;

Rowlinson, Rachel ;

Klinowska, Teresa ;

Richmond, Graham H. P. ;

Cantarini, Mireille ;

Kim, Dong-Wan ;

Ranson, Malcolm R. ;

Pao, William .

CANCER DISCOVERY, 2014, 4 (09) :1046-1061

← 1 2 3 4 5 6 7 →